PMC SCIENCE AND PUBLIC POLICY COMMITTEES
MEETING AGENDA

December 2, 12:00 – 2:00 p.m. ET
Link to webinar:
https://permedcoalition.webex.com/permedcoalition/onstage/g.php?MTID=ed1d61d185cb326639e89fbe31608e2ea
(passcode: pmc123)
Dial 202-800-9984 and enter meeting ID 825756.
Note: You will be muted upon entry. Please dial 4* to unmute your line.

12:00 p.m. ET  Welcome & Introduction
Edward Abrahams
President
Personalized Medicine Coalition

12:05 p.m. ET  Dynamic Scoring and Personalized Medicine
• Douglas Holtz-Eakin, Ph.D.
  President
  American Action Forum

12:35 p.m. ET  Business Meeting
Cynthia A. Bens
Senior Vice President, Public Policy
Personalized Medicine Coalition

  • Public Policy Updates
    • Congressional Activities
      ■ Congressional Personalized Medicine Caucus
        • Congress and Personalized Medicine: The Perspectives of the Co-Chairs of the Personalized Medicine Caucus

      ■ 21st Century Cures 2.0 (Reps. DeGette and Upton press release)
        • PMC comment letter (July 16, 2021)

      ■ Precision Medicine Answers for Kids Today Act (Reps. Swalwell, Peters and Emmer press release)

(continued)
- FY 2022 appropriations for FDA and NIH
  - PMC outside witness testimonies (May 2021)
  - Ad Hoc Group Sign-on Letter (November 15, 2021)

  o Regulation
    - Nomination of Dr. Robert Califf as FDA Commissioner
      - Friends of Cancer Research Sign-on Letter (December 1, 2021)
    - User fee program reauthorization
      - PMC’s remarks during FDA’s Public Workshop on the Seventh Reauthorization of the Prescription Drug User Fee Act (September 28, 2021)
      - PMC comment letter on Medical Device User Fee Amendments for Fiscal Years 2023 Through 2027 (November 27, 2020)
    - STRIPE: A Collaborative Community in Pharmacogenomics (website)

  o Coverage and Reimbursement
    - Directions for CMMI’s Oncology Care First Model
    - Proposed recension of CMS’ Most Favored Nation (MFN) Model
      - PMC comment letter (October 12, 2021)
    - Withdrawal of CMS’ Medicare Coverage of Innovative Technology (MCIT) and Definition of “Reasonable and Necessary” (R&N) final rule
      - PMC comment letter (October 15, 2021)
    - National Government Services’ proposed local coverage determination on Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms
      - PMC comment letter (November 13, 2021)

  o Evidence-Based Medicine
    - National Committee for Quality Assurance’s proposed changes to colorectal cancer screening measure
      - PMC comment letter (October 21, 2021)

  o Working Group Updates
    - Pharmaceutical & Diagnostics Working Group
    - Patient Advocacy Organization Working Group

(continued)
Daryl Pritchard, Ph.D.
Senior Vice President, Science Policy
Personalized Medicine Coalition

- **Science Policy Updates**
  
  - *A Research Program for Advancing Personalized Medicine in 2022: An Overview of Initiatives to Evaluate Progress in Health Care, Assess Clinical and Economic Value, and Examine Clinical Integration Strategies*
    
    - Research Program Study No. 9: "Addressing Disparities and Improving Health Equity in Research Advancing Personalized Medicine"
    
    - Research Program Study No. 3: “Payer Perspectives and Policies on Personalized Medicine: A Landscape Analysis”
      - [Project Overview](#)
  
  - **Working Group Updates**
    
    - Pharmacogenomics Working Group
    - Health Care Working Group

David Davenport
Manager, Public Policy
Personalized Medicine Coalition

- **PMC’s 2022 Policy Agenda**

  1:50 p.m. ET  **New Business**

  2:00 p.m. ET  **Conclusion**